Научно-исследовательский центр «Онкотераностика»

Публикации Толмачева В. М.

  1. Xu, T., Ding, H., Vorobyeva, A., Oroujeni, M., Orlova, A., Tolmachev, V.,  Gräslund, T.  Drug conjugates based on a monovalent affibody targeting vector can efficiently eradicate HER2 positive human tumors in an experimental mouse model //Cancers. – 2021. – Vol. 13. – No. 1. – P. 85. 
    DOI: 10.3390/cancers13010085  
    https://www.mdpi.com/2072-6694/13/1/85
  2. Abouzayed, A., Tano, H., Nagy, A., Rinne, S.S., Wadeea, F., Kumar, S., Westerlund, K., Tolmachev, V., Karlstrom, A.E., Orlova, A. Preclinical evaluation of the grpr-targeting antagonist rm26 conjugated to the albumin-binding domain for grpr-targeting therapy of cancer //Pharmaceutics. – 2020. – Vol. 12. – No. 10. – P. 977.
    DOI: 10.3390/pharmaceutics12100977
    https://www.mdpi.com/1999-4923/12/10/977
  3. Leitao, C.D., Rinne, S.S., Altai, M., Vorontsova, O., Dunas, F., Jonasson, P., Tolmachev, V., Lofblom, J., Stahl, S., Orlova, A. Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model //Pharmaceutics. – 2020. – Vol. 12. – No. 6. – P. 551.
    DOI: 10.3390/pharmaceutics12060551
    https://www.mdpi.com/1999-4923/12/6/551
  4. Vorobyeva, A., Konovalova, E., Xu, T., Schulga, A., Altai, M., Garousi, J., Rinne, S.S., Orlova, A., Tolmachev, V., Deyev, S. Feasibility of imaging epcam expression in ovarian cancer using radiolabeled darpin ec1 //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 9. – P. 3310.
    DOI: 10.3390/ijms21093310
    https://www.mdpi.com/1422-0067/21/9/3310/htm
  5. Ding, H., Altai, M., Yin, W., Lindbo, S., Liu, H., Garousi, J., Xu, T., Orlova, A., Tolmachev, V., Hober, S., Graslund, T. HER2-specific pseudomonas exotoxin a pe25 based fusions: Influence of targeting domain on target binding, toxicity, and in vivo biodistribution //Pharmaceutics. – 2020. – Vol. 12. – No. 4. – P. 391.
    DOI: 10.3390/pharmaceutics12040391
    https://www.mdpi.com/1999-4923/12/4/391/htm
  6. Tolmachev, V., Orlova, A. Affibody molecules as targeting vectors for PET imaging //Cancers. – 2020. – Vol. 12. – No. 3. – P. 651.
    DOI: 10.3390/cancers12030651
    https://www.mdpi.com/2072-6694/12/3/651
  7. Rinne, S.S., Leitao, C.D., Saleh-Nihad, Z., Mitran, B., Tolmachev, V., Stahl, S., Lofblom, J., Orlova, A. Benefit of later-time-point PET imaging of her3 expression using optimized radiocobalt-labeled affibody molecules //International journal of molecular sciences. – 2020. – Vol. 21. – No. 6. – P. 1972.
    DOI: 10.3390/ijms21061972
    https://www.mdpi.com/1422-0067/21/6/1972
  8. Deyev, S.M., Vorobyeva, A., Schulga, A., Abouzayed, A., Gunther, T., Garousi, J., Konovalova, E., Ding, H., Graslund, T., Orlova, A., Tolmachev, V. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1 //International Journal of Biological Macromolecules. – 2020. – Vol. 145. – P. 216-225.
    DOI: 10.1016/j.ijbiomac.2019.12.147
    https://www.sciencedirect.com/science/article/pii/S0141813019393808
  9. Rinne, S.S., Xu, T., Leitao, C.D., Stahl, S., Lofblom, J., Orlova, A., Tolmachev, V., Vorobyeva, A. Influence of residualizing properties of the radiolabel on radionuclide molecular imaging of HER3 using affibody molecules //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 4. – P. 1312.
    DOI: 10.3390/ijms21041312
  10. Altai, M., Vorobyeva, A., Tolmachev, V., Karlstrom, A.E., Westerlund, K. Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting //Peptide Nucleic Acids. – Humana, New York, NY, 2020. – P. 283-304.
    DOI: 10.1007/978-1-0716-0243-0_18
  11. Larkina, M.S., Ozerskaya, A.V., Podrezova, E.V., Belousov, M.V., Tolmachev, V., Zhdankin, V.V., Yusubov, M.S. Efficient Synthesis of w-[18F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission //European Journal of Organic Chemistry. – 2020.– P. 6375-6381.
    DOI: 10.1002/ejoc.202000934
    https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/ejoc.202000934
  12. Alhuseinalkhudhur, A., Lubberink, M., Lindman, H., Tolmachev, V., Frejd, F.Y., Feldwisch, J., Velikyan, I., Sorensen, J. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer //EJNMMI research. – 2020. – Vol. 10. – No. 1. – P. 1-10.
    DOI: 10.1186/s13550-020-0603
    https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-0603-9
  13. Lundmark, F., Abouzayed, A., Mitran, B., Rinne, S.S., Varasteh, Z., Larhed, M., Tolmachev, V., Rosenstrom, U., Orlova, A. Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—optimization of the affinity towards PSMA by linker modification in murine model //Pharmaceutics. – 2020. – Vol. 12. – No. 7. – P. 614.
    DOI: 10.3390/pharmaceutics12070614
    https://www.mdpi.com/1999-4923/12/7/614
  14. Bragina, O.D., Vorobyeva, A.G., Tolmachev, V.M., Orlova, A.M., Chernov, V.I., Deyev, S.M., Proshkina, G.N., Shulga, A.A., Larkina, M.S., Medvedeva, A.A., Zelchan, R.V. In vitro and in vivo evaluation of the radiochemical compound based on 99mtechnetium labelled DARPin9_29 for molecular visualization of malignancies overexpressing Her2/neu [In vitro и in vivo Оценка радиохимического соединения на основе меченного 99mTс каркасного белка  DARPin9_29 для молекулярной визуализации злокачественных образований с гиперэкспрессией  Her2/neu] //Medical Radiology and Radiation Safety. – 2020. – Vol. 65. – No. 1. – P. 37-41.
    DOI: 10.12737/1024-6177-2020-65-1-37-41
    https://medradiol.fmbafmbc.ru/journal_medradiol/abstracts/2020/1/37-41_Bragina_et_al.pdf
  15. Mitran, B., Rinne, S.S., Konijnenberg, M.W., Maina, T., Nock, B.A., Altai, M., Vorobyeva, A., Larhed, M., Tolmachev, V., de Jong, M., Rosenstrom, U., Orlova, A. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26 //International journal of cancer. – 2019. – Vol. 145. – No. 12. – P. 3347-3358.
    DOI: 10.1002/ijc.32401
    https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.32401
  16. Mitran, B., Thisgaard, H., Rinne, S., Dam, J.H., Azami, F., Tolmachev, V., Orlova, A., Rosenstrom, U. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26 //Scientific Reports. – 2019. – Vol. 9. – No. 1. – P. 1-11. 
    DOI: 10.1038/s41598-019-52914-y
    https://www.nature.com/articles/s41598-019-52914-y
  17. Rinne, S.S., Dahlsson Leitao, C., Gentry, J., Mitran, B., Abouzayed, A., Tolmachev, V., Stahl, S., Lofblom, J., Orlova, A.Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules //Scientific reports. – 2019. – Vol. 9. – No. 1. – P. 1-10.
    https://doi.org/10.1038/s41598-019-54149-3
    https://www.nature.com/articles/s41598-019-54149-3
  18. Rinne, S.S., Leitao, C.D., Mitran, B., Bass, T.Z., Andersson, K.G., Tolmachev, V., Stahl, S., Lofblom, J., Orlova, A. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111 //Scientific reports. – 2019. – Vol. 9. – No. 1. – P. 1-11.
    DOI: 10.1038/s41598-018-36827-w
    https://www.nature.com/articles/s41598-018-36827-w
  19. Huizing, F.J., Garousi, J., Lok, J., Franssen, G., Hoeben, B.A.W., Frejd, F.Y., Boerman, O.C., Bussink, J., Tolmachev, V., Heskamp, S. CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models //Scientific reports. – 2019. – Vol. 9. – No. 1. – P. 1-10.
    DOI: 10.1038/s41598-019-54824-5
    https://www.nature.com/articles/s41598-019-54824-5
  20. Rosestedt, M., Andersson, K.G., Rinne, S.S., Leitao, C.D., Mitran, B., Vorobyeva, A., Stahl, S., Lofblom, J., Tolmachev, V., Orlova, A. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake //Scientific reports. – 2019. – Vol. 9. – No. 1. – P. 1-10.
    DOI: 10.1038/s41598-019-43145-2
  21. Garousi, J., Huizing, F.J., Vorobyeva, A., Mitran, B., Andersson, K.G., Leitao, C.D., Frejd, F.Y., Lofblom, J., Bussink, J., Orlova, A., Heskamp, S., Tolmachev, V. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts //Scientific Reports. – 2019. – Vol. 9. – No. 1. – P. 1-12.
    DOI: 10.1038/s41598-019-51445-w
    https://www.nature.com/articles/s41598-019-51445-w.pdf?origin=ppub
  22. Vorobyeva, A., Schulga, A., Konovalova, E., Guler, R., Lofblom, J., Sandstrom, M., Garousi, J., Chernov, V., Bragina, O., Orlova, A., Tolmachev, V., Deyev, S.M. Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3 //Scientific reports. – 2019. – Vol. 9. – No. 1. – P. 1-11.
    DOI: 10.1038/s41598-019-45795-8
    https://www.nature.com/articles/s41598-019-45795-8
  23. Mitran, B., Varasteh, Z., Abouzayed, A., Rinne, S.S., Puuvuori, E., De Rosa, M., Larhed, M., Tolmachev, V., Orlova, A., Rosenstrom, U. Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer //Cancers. – 2019. – Vol. 11. – No. 9. – P. 1371.
    DOI: 10.3390/cancers11091371
    https://www.mdpi.com/2072-6694/11/9/1371
  24. Oroujeni, M., Abouzayed, A., Lundmark, F., Mitran, B., Orlova, A., Tolmachev, V., Rosenstrom, U. Evaluation of tumor-targeting properties of an antagonistic bombesin analogue RM26 conjugated with a non-residualizing radioiodine label comparison with a radiometal-labelled counterpart //Pharmaceutics. – 2019. – Vol. 11. – No. 8. – P. 380.
    DOI: 10.3390/pharmaceutics11080380
    https://www.mdpi.com/1999-4923/11/8/380
  25. Ding, H., Altai, M., Rinne, S.S., Vorobyeva, A., Tolmachev, V., Graslund, T., Orlova, A. Incorporation of a hydrophilic spacer reduces hepatic uptake of her2-targeting a?body–dm1 drug conjugates //Cancers. – 2019. – Vol. 11. – No. 8. – P. 1168.
    DOI: 10.3390/cancers11081168
    https://www.mdpi.com/2072-6694/11/8/1168
  26. von Witting, E., Garousi, J., Lindbo, S., Vorobyeva, A., Altai, M., Oroujeni, M., Mitran, B., Orlova, A., Hober, S., Tolmachev, V. Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 //European journal of pharmaceutics and biopharmaceutics. – 2019. – Vol. 140. – P. 109-120.
    DOI: 10.1016/j.ejpb.2019.05.008
    https://www.sciencedirect.com/science/article/pii/S0939641119301754
  27. Vorobyeva, A., Schulga, A., Rinne, S.S., Gunther, T., Orlova, A., Deyev, S., Tolmachev, V. Indirect radioiodination of darpin g3 using n-succinimidyl-para-iodobenzoate improves the contrast of her2 molecular imaging //International journal of molecular sciences. – 2019. – Vol. 20. – No. 12. – P. 3047.
    DOI: 10.3390/ijms20123047
    https://www.mdpi.com/1422-0067/20/12/3047
  28. Westerlund, K., Vorobyeva, A., Mitran, B., Orlova, A., Tolmachev, V., Karlstrom, A.E., Altai, M. Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting //Biomaterials. – 2019. – Vol. 203. – P. 73-85.
    DOI: 10.1016/j.biomaterials.2019.02.012
    https://www.sciencedirect.com/science/article/pii/S0142961219300973
  29. Vorobyeva, A., Schulga, A., Konovalova, E., Guler, R., Mitran, B., Garousi, J., Rinne, S., Lofblom, J., Orlova, A., Deyev, S., Tolmachev, V. Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 //International journal of oncology. – 2019. – Vol. 54. – No. 4. – P. 1209-1220.
    DOI: 10.3892/ijo.2019.4712
    https://www.spandidos-publications.com/10.3892/ijo.2019.4712
  30. Deyev, S., Vorobyeva, A., Schulga, A., Proshkina, G., Guler, R., Lofblom, J., Mitran, B., Garousi, J., Altai, M., Buijs, J., Chernov, V., Orlova, A., Tolmachev, V. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties //Molecular pharmaceutics. – 2019. – Vol. 16. – No. 3. – P. 995-1008.
    DOI: 10.1021/acs.molpharmaceut.8b00922
    https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.8b00922
  31. Leitao, C.D., Rinne, S.S., Mitran, B., Vorobyeva, A., Andersson, K.G., Tolmachev, V., Stahl, S., Lofblom, J., Orlova, A. Molecular design of HER3-targeting affibody molecules: Influence of chelator and presence of HEHEHE-Tag on biodistribution of 68 Ga-labeled tracers //International journal of molecular sciences. – 2019. – Vol. 20. – No. 5. – P. 1080.
    DOI: 10.3390/ijms20051080
    https://www.mdpi.com/1422-0067/20/5/1080
  32. Molavipordanjani, S., Tolmachev, V., Hosseinimehr, S.J. Basic and practical concepts of radiopharmaceutical purification methods //Drug discovery today. – 2019. – Vol. 24. – No. 1. – P. 315-324.
    DOI: 10.1016/j.drudis.2018.09.018
  33. Liu, H., Lindbo, S., Ding, H., Altai, M., Garousi, J., Orlova, A., Tolmachev, V., Hober, S., Graslund, T. Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A //International Journal of Oncology. – 2019. – Vol. 55. – No. 1. – P. 309-319. 
    DOI: 10.3892/ijo.2019.4814
  34. Mitran, B., Andersson, K.G., Lindstrom, E., Garousi, J., Rosestedt, M., Tolmachev, V., Stahl, S., Orlova, A., Lofblom, J. Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377 //Oncology Reports. – 2019. – Vol. 41. – No. 1. – P. 534-542.
    DOI: 10.3892/or.2018.6792
  35. Garousi, J., Lindbo, S., Borin, J., von Witting, E., Vorobyeva, A., Oroujeni, M., Mitran, B., Orlova, A., Buijs, J., Tolmachev, V., Hober, S. Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumors //European Journal of Pharmaceutics and Biopharmaceutics. – 2019. – Vol. 134. – P. 37-48.
    DOI: 10.1016/j.ejpb.2018.11.004
  36. Vorobyeva, A., Westerlund, K., Mitran, B., Altai, M., Rinne, S., Sorensen, J., Orlova, A., Tolmachev, V., Karlstrom, A.E. Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy //Scientific Reports. – 2018. – Vol. 8. – No. 1:9643. – P. 1-10.
    DOI: 10.1038/s41598-018-27886-0
  37. Honarvar, H., Calce, E., Doti, N., Langella, E., Orlova, A., Buijs, J., D'Amato, V., Bianco, R., Saviano, M., Tolmachev, V., De Luca, S. Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe //Scientific Reports. – 2018. – Vol. 8. – No. 1:2998. – P. 1-10. 
    DOI: 10.1038/s41598-018-21283-3
  38. Nordling, S., Brannstrom, J., Carlsson, F., Lu, B., Salvaris, E., Wanders, A., Buijs, J., Estrada, S., Tolmachev, V., Cowan, P.J., Lorant, T., Magnusson, P.U. Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation: Preclinical investigations in pig and mouse //Scientific Reports. – 2018. – Vol. 8. – No. 1:5220. – P. 1-10. DOI: 10.1038/s41598-018-21463-1
  39. Tolmachev, V., Gronroos, T.J., Yim, C.-B., Garousi, J., Yue, Y., Grimm, S., Rajander, J., Perols, A., Haaparanta-Solin, M., Solin, O., Ferdani, R., Orlova, A., Anderson, C.J., Karlstrom, A.E. Molecular design of radiocopper-labelled Affibody molecules //Scientific Reports. – 2018. – Vol. 8. – No. 1:6542. – P. 1-10.
    DOI: 10.1038/s41598-018-24785-2
  40. Altai, M., Liu, H., Ding, H., Mitran, B., Edqvist, P.-H., Tolmachev, V., Orlova, A., Graslund, T. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors //Journal of Controlled Release. – 2018.  – No. 228. – P. 84-95.
    DOI: 10.1016/j.jconrel.2018.08.040
  41. Orlova, A., Bass, T.Z., Rinne, S.S., Leitao, C.D., Rosestedt, M., Atterby, C., Gudmundsdotter, L., Frejd, F.Y., Lofblom, J., Tolmachev, V., Stahl, S. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab //Molecular Pharmaceutics. – 2018. – Vol. 15. – No. 18. – P. 3394-3403.
    DOI: 10.1021/acs.molpharmaceut.8b00393
  42. Oroujeni, M., Andersson, K.G., Steinhardt, X., Altai, M., Orlova, A., Mitran, B., Vorobyeva, A., Garousi, J., Tolmachev, V., Lofblom, J. Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules //Amino Acids. – 2018. – Vol. 50. – No. 8. – P. 981-994.
    DOI: 10.1007/s00726-018-2571-1
  43. Lindbo, S., Garousi, J., Mitran, B., Vorobyeva, A., Oroujeni, M., Orlova, A., Hober, S., Tolmachev, V. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111 In and 68 Ga //Molecular Pharmaceutics. – 2018. – Vol. 15. – No. 7. – P. 2674-2683.
    DOI: 10.1021/acs.molpharmaceut.8b00204
  44. Krasniqi, A., D’Huyvetter, M., Devoogdt, N., Frejd, F.Y., Sorensen, J., Orlova, A., Keyaerts, M., Tolmachev, V. Same-day imaging using small proteins: Clinical experience and translational prospects in oncology //Journal of Nuclear Medicine. – 2018. – Vol. 59. – No. 6. – P. 885-891.
    DOI: 10.2967/jnumed.117.199901
  45. Summer, D., Garousi, J., Oroujeni, M., Mitran, B., Andersson, K.G., Vorobyeva, A., Lofblom, J., Orlova, A., Tolmachev, V., Decristoforo, C. Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression //Molecular Pharmaceutics. – 2018. – Vol. 15. – No. 1. – P. 175-185.
    DOI: 10.1021/acs.molpharmaceut.7b00787
  46. Lindbo, S., Garousi, J., Mitran, B., Altai, M., Buijs, J., Orlova, A., Hober, S., Tolmachev, V. Radionuclide tumor targeting using ADAPT scaffold proteins: Aspects of label positioning and residualizing properties of the label //Journal of Nuclear Medicine. – 2018. – Vol. 59. – No. 1. – P. 93-99.
    DOI: 10.2967/jnumed.117.197202
  47. Vorobyeva, A., Bragina, O., Altai, M., Mitran, B., Orlova, A., Shulga, A., Proshkina, G., Chernov, V., Tolmachev, V., Deyev, S. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9-29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors //Contrast Media and Molecular Imaging. – 2018. – No. 6930425. 
    DOI: 10.1155/2018/6930425
  48. Mitran, B., Guler, R., Roche, F.P., Lindstrom, E., Selvaraju, R.K., Fleetwood, F., Rinne, S.S., Claesson-Welsh, L., Tolmachev, V., Stahl, S., Orlova, A., Lofblom, J. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: Proof-of-principle in a murine model //Theranostics. – 2018. – Vol. 8. – No. 16. – P. 4462-4476.
    DOI: 10.7150/thno.24395
  49. Rosestedt, M., Andersson, K.G., Mitran, B., Rinne, S.S., Tolmachev, V., Lofblom, J., Orlova, A., Stahl, S. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression //International Journal of Oncology. – 2017. – Vol. 51. – No. 6. – P. 1765-1774.
    DOI: 10.3892/ijo.2017.4152
  50. Garousi, J., Lindbo, S., Mitran, B., Buijs, J., Vorobyeva, A., Orlova, A., Tolmachev, V., Hober, S. Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-Terminus with indium-111 or technetium-99m //Scientific Reports. – 2017. – Vol. 7. – No. 1:14780. – P. 1-10. 
    DOI:10.1038/s41598-017-15366-w
  51. Garousi, J., Andersson, K.G., Dam, J.H., Olsen, B.B., Mitran, B., Orlova, A., Buijs, J., Stahl, S., Lofblom, J., Thisgaard, H., Tolmachev, V. The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule //Scientific Reports. – 2017. – Vol. 7. – No. 1:5961. – P. 1-10.
    DOI: 10.1038/s41598-017-05700-7
  52. Altai, M., Membreno, R., Cook, B., Tolmachev, V., Zeglis, B.M. Pretargeted imaging and therapy //Journal of Nuclear Medicine. – 2017. – Vol. 58. – No. 10. – P. 1553-1559.
    DOI: 10.2967/jnumed.117.189944
  53. Mitran, B., Thisgaard, H., Rosenstrom, U., Dam, J.H., Larhed, M., Tolmachev, V., Orlova, A. High contrast pet imaging of GRPR expression in prostate cancer using cobalt-labeled bombesin antagonist RM26 //Contrast Media and Molecular Imaging – 2017. – No. 6873684 
    DOI: 10.1155/2017/6873684
  54. Sandberg, D., Tolmachev, V., Velikyan, I., Olofsson, H., Wennborg, A., Feldwisch, J., Carlsson, J., Lindman, H., Sorensen, J. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT (2017) European Journal of Nuclear Medicine and Molecular Imaging, 44 (8), pp. 1337-1346.
    DOI: 10.1007/s00259-017-3650-3
  55. Tolmachev, V., Yim, C.-B., Rajander, J., Perols, A., Karlstrom, A.E., Haaparanta-Solin, M., Gronroos, T.J., Solin, O., Orlova, A. Comparative evaluation of anti-HER2 affibody molecules labeled with 64Cu using NOTA and NODAGA (2017) Contrast Media and Molecular Imaging, 2017, статья № 8565802, .
    DOI: 10.1155/2017/8565802
  56. Bass, T.Z., Rosestedt, M., Mitran, B., Frejd, F.Y., Lofblom, J., Tolmachev, V., Stahl, S., Orlova, A. In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct (2017) Scientific Reports, 7, статья № 43118, .
    DOI: 10.1038/srep43118
  57. Honarvar, H., Muller, C., Cohrs, S., Haller, S., Westerlund, K., Karlstrom, A.E., van der Meulen, N.P., Schibli, R., Tolmachev, V. Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors (2017) Nuclear Medicine and Biology, 45, pp. 15-21.
    DOI: 10.1016/j.nucmedbio.2016.10.004
  58. Andersson, K.G., Oroujeni, M., Garousi, J., Mitran, B., Stahl, S., Orlova, A., Lofblom, J., Tolmachev, V. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator (2016) International Journal of Oncology, 49 (6), pp. 2285-2293.
    DOI: 10.3892/ijo.2016.3721
  59. Garousi, J., Lindbo, S., Honarvar, H., Velletta, J., Mitran, B., Altai, M., Orlova, A., Tolmachev, V., Hober, S. Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6 (2016) Bioconjugate Chemistry, 27 (11), pp. 2678-2688.
    DOI: 10.1021/acs.bioconjchem.6b00465
  60. Garousi, J., Honarvar, H., Andersson, K.G., Mitran, B., Orlova, A., Buijs, J., Lofblom, J., Frejd, F.Y., Tolmachev, V. Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX (2016) Molecular Pharmaceutics, 13 (11), pp. 3676-3687.
    DOI: 10.1021/acs.molpharmaceut.6b00502
  61. Altai, M., Liu, H., Orlova, A., Tolmachev, V., Graslund, T. Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin (2016) International Journal of Oncology, 49 (3), pp. 1185-1194.
    DOI: 10.3892/ijo.2016.3614
  62. Sandstrom, M., Lindskog, K., Velikyan, I., Wennborg, A., Feldwisch, J., Sandberg, D., Tolmachev, V., Orlova, A., Sorensen, J., Carlsson, J., Lindman, H., Lubberink, M. Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients (2016) Journal of Nuclear Medicine, 57 (6), pp. 867-871.
    DOI: 10.2967/jnumed.115.169342
  63. Westerlund, K., Honarvar, H., Norrstrom, E., Strand, J., Mitran, B., Orlova, A., Eriksson Karlstrom, A., Tolmachev, V. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules (2016) Molecular Pharmaceutics, 13 (5), pp. 1668-1678.
    DOI: 10.1021/acs.molpharmaceut.6b00089
  64. Mitran, B., Varasteh, Z., Selvaraju, R.K., Lindeberg, G., Sorensen, J., Larhed, M., Tolmachev, V., Rosenstrom, U., Orlova, A. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26 (2016) International Journal of Oncology, 48 (5), pp. 2124-2134.
    DOI: 10.3892/ijo.2016.3429
  65. Garousi, J., Andersson, K.G., Mitran, B., Pichl, M.-L., Stahl, S., Orlova, A., Lofblom, J., Tolmachev, V. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules (2016) International Journal of Oncology, 48 (4), pp. 1325-1332.
    DOI: 10.3892/ijo.2016.3369
  66. Li, X., Padhan, N., Sjostrom, E.O., Roche, F.P., Testini, C., Honkura, N., Sainz-Jaspeado, M., Gordon, E., Bentley, K., Philippides, A., Tolmachev, V., Dejana, E., Stan, R.V., Vestweber, D., Ballmer-Hofer, K., Betsholtz, C., Pietras, K., Jansson, L., Claesson-Welsh, L. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread (2016) Nature Communications, 7, статья № 11017, .
    DOI: 10.1038/ncomms11017
  67. Lindbo, S., Garousi, J., Astrand, M., Honarvar, H., Orlova, A., Hober, S., Tolmachev, V. Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins (2016) Bioconjugate Chemistry, 27 (3), pp. 716-726.
    DOI: 10.1021/acs.bioconjchem.5b00677
  68. Altai, M., Perols, A., Tsourma, M., Mitran, B., Honarvar, H., Robillard, M., Rossin, R., Ten Hoeve, W., Lubberink, M., Orlova, A., Karlstrom, A.E., Tolmachev, V. Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting (2016) Journal of Nuclear Medicine, 57 (3), pp. 431-436.
    DOI: 10.2967/jnumed.115.162248
  69. Kootala, S., Zhang, Y., Ghalib, S., Tolmachev, V., Hilborn, J., Ossipov, D.A. Control of growth factor binding and release in bisphosphonate functionalized hydrogels guides rapid differentiation of precursor cells in vitro (2016) Biomaterials Science, 4 (2), pp. 250-254.
    DOI: 10.1039/c5bm00355e
  70. Haylock, A.-K., Spiegelberg, D., Mortensen, A.C., Selvaraju, R.K., Nilvebrant, J., Eriksson, O., Tolmachev, V., Nestor, M.V. Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma (2016) International Journal of Oncology, 48 (2), pp. 461-470.
    DOI: 10.3892/ijo.2015.3290
  71. Honarvar, H., Westerlund, K., Altai, M., Sandstrom, M., Orlova, A., Tolmachev, V., Karlstrom, A.E. Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors (2016) Theranostics, 6 (1), pp. 93-103.
    DOI: 10.7150/thno.12766
  72. Chiotellis, A., Sladojevich, F., Mu, L., Muller Herde, A., Valverde, I.E., Tolmachev, V., Schibli, R., Ametamey, S.M., Mindt, T.L. Novel chemoselective 18F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions (2016) Chemical Communications, 52 (36), pp. 6083-6086.
    DOI: 10.1039/c6cc01982j
  73. Sorensen, J., Velikyan, I., Sandberg, D., Wennborg, A., Feldwisch, J., Tolmachev, V., Orlova, A., Sandstrom, M., Lubberink, M., Olofsson, H., Carlsson, J., Lindman, H. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT (2016) Theranostics, 6 (2), pp. 262-271.
    DOI: 10.7150/thno.13502
  74. Rosestedt, M., Andersson, K.G., Mitran, B., Tolmachev, V., Lofblom, J., Orlova, A., Stahl, S. Affibody-mediated PET imaging of HER3 expression in malignant tumours (2015) Scientific Reports, 5, статья № 15226, .
    DOI: 10.1038/srep15226
  75. Garousi, J., Lindbo, S., Nilvebrant, J., Astrand, M., Buijs, J., Sandstrom, M., Honarvar, H., Orlova, A., Tolmachev, V., Hober, S. ADAPT, a novel scaffold protein-based probe for radionuclide imaging of molecular targets that are expressed in disseminated cancers (2015) Cancer Research, 75 (20), pp. 4364-4371.
    DOI: 10.1158/0008-5472.CAN-14-3497
  76. Westerlund, K., Honarvar, H., Tolmachev, V., Eriksson Karlstrom, A. Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting (2015) Bioconjugate Chemistry, 26 (8), pp. 1724-1736.
    DOI: 10.1021/acs.bioconjchem.5b00292
  77. Liu, H., Seijsing, J., Frejd, F.Y., Tolmachev, V., Graslund, T. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain (2015) International Journal of Oncology, 47 (2), pp. 601-609.
    DOI: 10.3892/ijo.2015.3027
  78. Andersson, K.G., Rosestedt, M., Varasteh, Z., Malm, M., Sandstrom, M., Tolmachev, V., Lofblom, J., Stahl, S., Orlova, A. Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors (2015) Oncology Reports, 34 (2), pp. 1042-1048.
    DOI: 10.3892/or.2015.4046
  79. Varasteh, Z., Mitran, B., Rosenstrom, U., Velikyan, I., Rosestedt, M., Lindeberg, G., Sorensen, J., Larhed, M., Tolmachev, V., Orlova, A. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 (2015) Nuclear Medicine and Biology, 42 (5), pp. 446-454.
    DOI: 10.1016/j.nucmedbio.2014.12.009
  80. Strand, J., Nordeman, P., Honarvar, H., Altai, M., Orlova, A., Larhed, M., Tolmachev, V. Site-specific radioiodination of HER2-targeting affibody molecules using 4-iodophenethylmaleimide decreases renal uptake of radioactivity (2015) ChemistryOpen, 4 (2), pp. 174-182.
    DOI: 10.1002/open.201402097
  81. Mitran, B., Altai, M., Hofstrom, C., Honarvar, H., Sandstrom, M., Orlova, A., Tolmachev, V., Graslund, T. Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression (2015) Amino Acids, 47 (2), pp. 303-315.
    DOI: 10.1007/s00726-014-1859-z
  82. Honarvar, H., Garousi, J., Gunneriusson, E., Hoiden-Guthenberg, I., Altai, M., Widstrom, C., Tolmachev, V., Frejd, F.Y. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 Affibody molecule (2015) International Journal of Oncology, 46 (2), pp. 513-520.
    DOI: 10.3892/ijo.2014.2782
  83. Altai, M., Honarvar, H., Wallberg, H., Strand, J., Varasteh, Z., Rosestedt, M., Orlova, A., Dunas, F., Sandstrom, M., Lofblom, J., Tolmachev, V., Stahl, S. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re (2014) European Journal of Medicinal Chemistry, 87, pp. 519-528.
    DOI: 10.1016/j.ejmech.2014.09.082
  84. Tugues, S., Roche, F., Noguer, O., Orlova, A., Bhoi, S., Padhan, N., Akerud, P., Honjo, S., Selvaraju, R.K., Mazzone, M., Tolmachev, V., Claesson-Welsh, L. Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes (2014) PLoS ONE, 9 (9), статья № e107483, .
    DOI: 10.1371/journal.pone.0107483
  85. Sorensen, J., Sandberg, D., Sandstrom, M., Wennborg, A., Feldwisch, J., Tolmachev, V., Astrom, G., Lubberink, M., Garske-Roman, U., Carlsson, J., Lindman, H. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule (2014) Journal of Nuclear Medicine, 55 (5), pp. 730-735.
    DOI: 10.2967/jnumed.113.131243
  86. Tolmachev, V., Varasteh, Z., Honarvar, H., Hosseinimehr, S.J., Eriksson, O., Jonasson, P., Frejd, F.Y., Abrahmsen, L., Orlova, A. Imaging of platelet-derived growth factor receptor ? expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591 (2014) Journal of Nuclear Medicine, 55 (2), pp. 294-300.
    DOI: 10.2967/jnumed.113.121814
  87. Rosik, D., Thibblin, A., Antoni, G., Honarvar, H., Strand, J., Selvaraju, R.K., Altai, M., Orlova, A., Eriksson Karlstrom, A., Tolmachev, V. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the n-terminus via oxime formation with 18F-4-fluorobenzaldehyde (2014) Bioconjugate Chemistry, 25 (1), pp. 82-92.
    DOI: 10.1021/bc400343r
  88. Tolmachev, V., Orlova, A., Andersson, K. Methods for radiolabelling of monoclonal antibodies (2014) Methods in Molecular Biology, 1060, pp. 309-330.
    DOI: 10.1007/978-1-62703-586-6_16
  89. Altai, M., Orlova, A., Tolmachev, V. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine (2014) Current Pharmaceutical Design, 20 (14), pp. 2275-2292.
    DOI: 10.2174/13816128113196660667
  90. Tolmachev, V., Malmberg, J., Estrada, S., Eriksson, O., Orlova, A. Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution (2014) International Journal of Oncology, 45 (6), pp. 1998-2008.
    DOI: 10.3892/ijo.2014.2376
  91. Strand, J., Varasteh, Z., Eriksson, O., Abrahmsen, L., Orlova, A., Tolmachev, V. Gallium-68-labeled affibody molecule for PET Imaging of PDGFR? Expression in Vivo (2014) Molecular Pharmaceutics, 11 (11), pp. 3957-3964.
    DOI: 10.1021/mp500284t
  92. Honarvar, H., Strand, J., Perols, A., Orlova, A., Selvaraju, R.K., Karlstrom, A.E., Tolmachev, V. Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga-Compared to 111in-labeled conjugates (2014) Molecular Imaging, 13 (10), .
    DOI: 10.2310/7290.2014.00034
  93. Sandin, L.C., Orlova, A., Gustafsson, E., Ellmark, P., Tolmachev, V., Totterman, T.H., Mangsbo, S.M. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer (2014) Cancer immunology research, 2 (1), pp. 80-90.
    DOI: 10.1158/2326-6066.CIR-13-0067
  94. Varasteh, Z., Rosenstrom, U., Velikyan, I., Mitran, B., Altai, M., Honarvar, H., Rosestedt, M., Lindeberg, G., Sorensen, J., Larhed, M., Tolmachev, V., Orlova, A. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin (2014) Molecules, 19 (7), pp. 10455-10472.
    DOI: 10.3390/molecules190710455
  95. Orlova, A., Malm, M., Rosestedt, M., Varasteh, Z., Andersson, K., Selvaraju, R.K., Altai, M., Honarvar, H., Strand, J., Stahl, S., Tolmachev, V., Lofblom, J. Imaging of HER3-expressing xenografts in mice using a 99mTc(CO) 3-HEHEHE-ZHER3:08699 affibody molecule (2014) European Journal of Nuclear Medicine and Molecular Imaging, 41 (7), pp. 1450-1459.
    DOI: 10.1007/s00259-014-2733-7
  96. Altai, M., Wallberg, H., Honarvar, H., Strand, J., Orlova, A., Varasteh, Z., Sandstrom, M., Lofblom, J., Larsson, E., Strand, S.-E., Lubberink, M., Stah, S., Tolmachev, V. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: Preclinical assessment (2014) Journal of Nuclear Medicine, 55 (11), pp. 1842-1848.
    DOI: 10.2967/jnumed.114.140194
  97. Varasteh, Z., Aberg, O., Velikyan, I., Lindeberg, G., Sorensen, J., Larhed, M., Antoni, G., Sandstrom, M., Tolmachev, V., Orlova, A. In vitro and in vivo evaluation of a18F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging (2013) PLoS ONE, 8 (12), статья № e81932, .
    DOI: 10.1371/journal.pone.0081932
  98. Strand, J., Honarvar, H., Perols, A., Orlova, A., Selvaraju, R.K., Karlstrom, A.E., Tolmachev, V. Influence of Macrocyclic Chelators on the Targeting Properties of 68Ga-Labeled Synthetic Affibody Molecules: Comparison with 111In-Labeled Counterparts (2013) PLoS ONE, 8 (8), статья № e70028, .
    DOI: 10.1371/journal.pone.0070028
  99. Varasteh, Z., Velikyan, I., Lindeberg, G., Sorensen, J., Larhed, M., Sandstrom, M., Selvaraju, R.K., Malmberg, J., Tolmachev, V., Orlova, A. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging (2013) Bioconjugate Chemistry, 24 (7), pp. 1144-1153.
    DOI: 10.1021/bc300659k
  100. Hofstrom, C., Altai, M., Honarvar, H., Strand, J., Malmberg, J., Hosseinimehr, S.J., Orlova, A., Graslund, T., Tolmachev, V. Influence of position and composition of histidine containing tags on biodistribution of [99mTc(CO) 3]+-labeled affibody molecules (2013) Journal of Medicinal Chemistry, 56 (12), pp. 4966-4974.
    DOI: 10.1021/jm400218y
  101. Altai, M., Strand, J., Rosik, D., Selvaraju, R.K., Eriksson Karlstrom, A., Orlova, A., Tolmachev, V. Influence of nuclides and chelators on imaging using affibody molecules: Comparative evaluation of recombinant affibody molecules site-specifically labeled with 68Ga and 111In via maleimido derivatives of DOTA and NODAGA (2013) Bioconjugate Chemistry, 24 (6), pp. 1102-1109.
    DOI: 10.1021/bc300678y
  102. Orlova, A., Jonsson, A., Rosik, D., Lundqvist, H., Lindborg, M., Abrahmsen, L., Ekblad, C., Frejd, F.Y., Tolmachev, V. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein (2013) Journal of Nuclear Medicine, 54 (6), pp. 961-968.
    DOI: 10.2967/jnumed.112.110700
  103. Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L., Bass, T., Frejd, F.Y., Hoiden-Guthenberg, I., Varasteh, Z., Orlova, A., Tolmachev, V., Stahl, S., Lofblom, J. Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification (2013) PLoS ONE, 8 (5), статья № e62791, .
    DOI: 10.1371/journal.pone.0062791
  104. Honarvar, H., Jokilaakso, N., Andersson, K., Malmberg, J., Rosik, D., Orlova, A., Karlstrom, A.E., Tolmachev, V., Jarver, P. Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging (2013) Nuclear Medicine and Biology, 40 (3), pp. 378-386.
    DOI: 10.1016/j.nucmedbio.2012.12.009
  105. Orlova, A., Hofstrom, C., Strand, J., Varasteh, Z., Sandstrom, M., Andersson, K., Tolmachev, V., Graslund, T. +-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours (2013) European Journal of Nuclear Medicine and Molecular Imaging, 40 (3), pp. 439-449.
    DOI: 10.1007/s00259-012-2284-8
  106. Magnusson, K., Sehlin, D., Syvanen, S., Svedberg, M.M., Philipson, O., Soderberg, L., Tegerstedt, K., Holmquist, M., Gellerfors, P., Tolmachev, V., Antoni, G., Lannfelt, L., H?akanall, H., Nilsson, L.N.G. Specific uptake of an amyloid-? protofibril-binding antibody-tracer in A?PP transgenic mouse brain (2013) Journal of Alzheimer's Disease, 37 (1), pp. 29-40.
    DOI: 10.3233/JAD-130029
  107. Hosseinimehr, S.J., Tolmachev, V., Orlova, A. Liver uptake of radiolabeled targeting proteins and peptides: Considerations for targeting peptide conjugate design (2012) Drug Discovery Today, 17 (21-22), pp. 1224-1232.
    DOI: 10.1016/j.drudis.2012.07.002
  108. Perols, A., Honarvar, H., Strand, J., Selvaraju, R., Orlova, A., Eriksson Karlstrom, A., Tolmachev, V. Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules (2012) Bioconjugate Chemistry, 23 (8), pp. 1661-1670.
    DOI: 10.1021/bc3002369
  109. Feldwisch, J., Tolmachev, V. Engineering of affibody molecules for therapy and diagnostics (2012) Methods in Molecular Biology, 899, pp. 103-126.
    DOI: 10.1007/978-1-61779-921-1_7
  110. Tolmachev, V., Tran, T.A., Rosik, D., Sjoberg, A., Abrahmsen, L., Orlova, A. Tumor targeting using affibody molecules: Interplay of affinity, target expression level, and binding site composition (2012) Journal of Nuclear Medicine, 53 (6), pp. 953-960.
    DOI: 10.2967/jnumed.111.101527
  111. Lindberg, H., Hofstrom, C., Altai, M., Honorvar, H., Wallberg, H., Orlova, A., Stahl, S., Graslund, T., Tolmachev, V. Evaluation of a HER2-targeting Affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus (2012) Tumor Biology, 33 (3), pp. 641-651.
    DOI: 10.1007/s13277-011-0305-z
  112. Altai, M., Wallberg, H., Orlova, A., Rosestedt, M., Hosseinimehr, S.J., Tolmachev, V., Stahl, S. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules (2012) Amino Acids, 42 (5), pp. 1975-1985.
    DOI: 10.1007/s00726-011-0927-x
  113. Altai, M., Perols, A., Karlstrom, A.E., Sandstrom, M., Boschetti, F., Orlova, A., Tolmachev, V. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA (2012) Nuclear Medicine and Biology, 39 (4), pp. 518-529.
    DOI: 10.1016/j.nucmedbio.2011.10.013
  114. Barta, P., Malmberg, J., Melicharova, L., Strandgard, J., Orlova, A., Tolmachev, V., Laznicek, M., Andersson, K. Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line (2012) International Journal of Oncology, 40 (5), pp. 1677-1682.
    DOI: 10.3892/ijo.2011.1307
  115. Evans-Axelsson, S., Ulmert, D., Orbom, A., Peterson, P., Nilsson, O., Wennerberg, J., Strand, J., Wingardh, K., Olsson, T., Hagman, Z., Tolmachev, V., Bjartell, A., Lilja, H., Strand, S.-E. Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone (2012) Cancer Biotherapy and Radiopharmaceuticals, 27 (4), pp. 243-251.
    DOI: 10.1089/cbr.2011.1088
  116. Rosik, D., Orlova, A., Malmberg, J., Altai, M., Varasteh, Z., Sandstrom, M., Karlstrom, A.E., Tolmachev, V. Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging (2012) European Journal of Nuclear Medicine and Molecular Imaging, 39 (4), pp. 693-702.
    DOI: 10.1007/s00259-011-2016-5
  117. Malmberg, J., Perols, A., Varasteh, Z., Altai, M., Braun, A., Sandstrom, M., Garske, U., Tolmachev, V., Orlova, A., Eriksson Karlstrom, A. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts (2012) European Journal of Nuclear Medicine and Molecular Imaging, 39 (3), pp. 481-492.
    DOI: 10.1007/s00259-011-1992-9
  118. Tolmachev, V., Malmberg, J., Hofstrom, C., Abrahmsen, L., Bergman, T., Sjoberg, A., Sandstrom, M., Graslund, T., Orlova, A. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-Z IGF1R:4551 (2012) Journal of Nuclear Medicine, 53 (1), pp. 90-97.
    DOI: 10.2967/jnumed.111.090829
  119. Heskamp, S., Laverman, P., Rosik, D., Boschetti, F., Van Der Graaf, W.T.A., Oyen, W.J.G., Van Laarhoven, H.W.M., Tolmachev, V., Boerman, O.C. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule Z HER2:2395 in a mouse model for ovarian cancer (2012) Journal of Nuclear Medicine, 53 (1), pp. 146-153.
    DOI: 10.2967/jnumed.111.093047
  120. Malmberg, J., Sandstrom, M., Wester, K., Tolmachev, V., Orlova, A. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: Focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody (2011) Nuclear Medicine and Biology, 38 (8), pp. 1093-1102.
    DOI: 10.1016/j.nucmedbio.2011.04.005
  121. Sandstrom, K., Haylock, A.-K., Velikyan, I., Spiegelberg, D., Kareem, H., Tolmachev, V., Lundqvist, H., Nestor, M. Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules (2011) Cancer Biotherapy and Radiopharmaceuticals, 26 (5), pp. 593-601.
    DOI: 10.1089/cbr.2011.0981
  122. Hosseinimehr, S.J., Tolmachev, V., Stenerlow, B. 125I-labeled quercetin as a novel DNA-targeted radiotracer (2011) Cancer Biotherapy and Radiopharmaceuticals, 26 (4), pp. 469-475.
    DOI: 10.1089/cbr.2010.0951
  123. Tolmachev, V., Feldwisch, J., Lindborg, M., Baastrup, B., Sandstrom, M., Orlova, A. Influence of an aliphatic linker between DOTA and synthetic ZHER2:342 Affibody molecule on targeting properties of the 111In-labeled conjugate (2011) Nuclear Medicine and Biology, 38 (5), pp. 697-706.
    DOI: 10.1016/j.nucmedbio.2010.11.013
  124. Hofstrom, C., Orlova, A., Altai, M., Wangsell, F., Graslund, T., Tolmachev, V. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with 99mTc, 111In, and 125I (2011) Journal of Medicinal Chemistry, 54 (11), pp. 3817-3826.
    DOI: 10.1021/jm200065e
  125. Tolmachev, V., Altai, M., Sandstrom, M., Perols, A., Karlstrom, A.E., Boschetti, F., Orlova, A. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules (2011) Bioconjugate Chemistry, 22 (5), pp. 894-902.
    DOI: 10.1021/bc100470x
  126. Malmberg, J., Tolmachev, V., Orlova, A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-A"DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines (2011) Experimental and Therapeutic Medicine, 2 (3), pp. 523-528.
    DOI: 10.3892/etm.2011.217
  127. Tolmachev, V. Radiobromine-labelled tracers for positron emission tomography: Possibilities and pitfalls (2011) Current Radiopharmaceuticals, 4 (2), pp. 76-89.
    DOI: 10.2174/1874471011104020076
  128. Malmberg, J., Tolmachev, V., Orlova, A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer - Targeting EGFR receptors in prostate cancer: Comparison of cellular processing of [111In]-labeled affibody molecule ZEGFR:2377 and cetuximab (2011) International Journal of Oncology, 38 (4), pp. 1137-1143.
    DOI: 10.3892/ijo.2011.915
  129. Tolmachev, V., Wallberg, H., Sandstrom, M., Hansson, M., Wennborg, A., Orlova, A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels (2011) European Journal of Nuclear Medicine and Molecular Imaging, 38 (3), pp. 531-539.
    DOI: 10.1007/s00259-010-1646-3
  130. Wllberg, H., Lofdahl, P.-K., Tschapalda, K., Uhlen, M., Tolmachev, V., Nygren, P.-K., Sthl, S. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand (2011) Protein Expression and Purification, 76 (1), pp. 127-135.
    DOI: 10.1016/j.pep.2010.10.008
  131. Wallberg, H., Orlova, A., Altai, M., Hosseinimehr, S.J., Widstrom, C., Malmberg, J., Stahl, S., Tolmachev, V. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties (2011) Journal of Nuclear Medicine, 52 (3), pp. 461-469.
    DOI: 10.2967/jnumed.110.083592
  132. Andersen, J.T., Pehrson, R., Tolmachev, V., Daba, M.B., Abrahmsen, L., Ekblad, C. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain (2011) Journal of Biological Chemistry, 286 (7), pp. 5234-5241.
    DOI: 10.1074/jbc.M110.164848
  133. Nestor, M., Sundstrom, M., Anniko, M., Tolmachev, V. Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas (2011) Nuclear Medicine and Biology, 38 (1), pp. 103-112.
    DOI: 10.1016/j.nucmedbio.2010.06.014
  134. Hosseinimehr, S.J., Orlova And, A., Tolmachev, V. Preparation and in vitro evaluation of 111In-CHX-A?-DTPA- labeled anti-VEGF monoclonal antibody bevacizumab (2010) Human Antibodies, 19 (4), pp. 107-111.
    DOI: 10.3233/HAB-2010-0234
  135. Tolmachev, V., Hofstrom, C., Malmberg, J., Ahlgren, S., Hosseinimehr, S.J., Sandstrom, M., Abrahmsen, L., Orlova, A., Graslund, T. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99mTc(CO)3]+, and shows improved biodistribution with reduced hepatic radioactivity accumulation (2010) Bioconjugate Chemistry, 21 (11), pp. 2013-2022.
    DOI: 10.1021/bc1002357
  136. Tolmachev, V., Stone-Elander, S., Orlova, A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: Prospects and pitfalls (2010) The Lancet Oncology, 11 (10), pp. 992-1000.
    DOI: 10.1016/S1470-2045(10)70088-7
  137. Ahlgren, S., Tolmachev, V. Radionuclide molecular imaging using affibody molecules (2010) Current Pharmaceutical Biotechnology, 11 (6), pp. 581-589.
    DOI: 10.2174/138920110792246609
  138. Tolmachev, V., Orlova, A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets (2010) Current Medicinal Chemistry, 17 (24), pp. 2636-2655.
    DOI: 10.2174/092986710791859397
  139. Ahlgren, S., Andersson, K., Tolmachev, V. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine (2010) Nuclear Medicine and Biology, 37 (5), pp. 539-546.
    DOI: 10.1016/j.nucmedbio.2010.02.009
  140. Tolmachev, V., Velikyan, I., Sandstrom, M., Orlova, A. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue (2010) European Journal of Nuclear Medicine and Molecular Imaging, 37 (7), pp. 1356-1367.
    DOI: 10.1007/s00259-009-1367-7
  141. Ahlgren, S., Orlova, A., Wallberg, H., Hansson, M., Sandstrom, M., Lewsley, R., Wennborg, A., Abrahmsen, L., Tolmachev, V., Feldwisch, J. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation Affibody molecule with a fundamentally reengineered scaffold (2010) Journal of Nuclear Medicine, 51 (7), pp. 1131-1138.
    DOI: 10.2967/jnumed.109.073346
  142. Lofblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Stahl, S., Frejd, F.Y. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications (2010) FEBS Letters, 584 (12), pp. 2670-2680.
    DOI: 10.1016/j.febslet.2010.04.014
  143. Baum, R.P., Prasad, V., Muller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., Feldwisch, J. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules (2010) Journal of Nuclear Medicine, 51 (6), pp. 892-897.
    DOI: 10.2967/jnumed.109.073239
  144. Tolmachev, V., Stone-Elander, S. Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods (2010) Biochimica et Biophysica Acta - General Subjects, 1800 (5), pp. 487-510.
    DOI: 10.1016/j.bbagen.2010.02.002
  145. Tolmachev, V., Rosik, D., Wallberg, H., Sjoberg, A., Sandstrom, M., Hansson, M., Wennborg, A., Orlova, A. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: Aspect of the injected tracer amount (2010) European Journal of Nuclear Medicine and Molecular Imaging, 37 (3), pp. 613-622.
    DOI: 10.1007/s00259-009-1283-x
  146. Orlova, A., Tran, T.A., Ekblad, T., Karlstrom, A.E., Tolmachev, V. 186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours (2010) European Journal of Nuclear Medicine and Molecular Imaging, 37 (2), pp. 260-269.
    DOI: 10.1007/s00259-009-1268-9
  147. Cheng, J., Engstrom, M., Ekberg, T., Nestor, M., Anniko, M., Tolmachev, V. The use of closo-dodecaborate-containing linker improves targeting of HNSCC xenografts with radioiodinated chimeric monoclonal antibody U36 (2010) Molecular Medicine Reports, 3 (1), pp. 155-160.
    DOI: 10.3892/mmr-00000233
  148. Feldwisch, J., Tolmachev, V., Lendel, C., Herne, N., Sjoberg, A., Larsson, B., Rosik, D., Lindqvist, E., Fant, G., Hoiden-Guthenberg, I., Galli, J., Jonasson, P., Abrahmsen, L. Design of an Optimized Scaffold for Affibody Molecules (2010) Journal of Molecular Biology, 398 (2), pp. 232-247.
    DOI: 10.1016/j.jmb.2010.03.002
  149. Tolmachev, V., Wallberg, H., Andersson, K., Wennborg, A., Lundqvist, H., Orlova, A. The influence of Bz-DOTA and CHX-A?-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: Implications for 114mIn- mediated targeting therapy (2009) European Journal of Nuclear Medicine and Molecular Imaging, 36 (9), pp. 1460-1468.
    DOI: 10.1007/s00259-009-1134-9
  150. Ekblad, T., Tolmachev, V., Orlova, A., Lendel, C., Abrahmsen, L., Karlstrom, A.E. Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody (2009) Biopolymers, 92 (2), pp. 116-123.
    DOI: 10.1002/bip.21142
  151. Ekblad, T., Orlova, A., Feldwisch, J., Wennborg, A., Karlstrom, A.E., Tolmachev, V. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules (2009) Bioorganic and Medicinal Chemistry Letters, 19 (14), pp. 3912-3914.
    DOI: 10.1016/j.bmcl.2009.03.083
  152. Tolmachev, V. Molecular imaging of EGFR: It's time to go beyond receptor expression: Reply (2009) Journal of Nuclear Medicine, 50 (7), p. 1196.
    DOI: 10.2967/jnumed.109.064188
  153. Tran, T.A., Rosik, D., Abrahmsen, L., Sandstrom, M., Sjoberg, A., Wallberg, H., Ahlgren, S., Orlova, A., Tolmachev, V. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging (2009) European Journal of Nuclear Medicine and Molecular Imaging, 36 (11), pp. 1864-1873.
    DOI: 10.1007/s00259-009-1176-z
  154. Ahlgren, S., Wallberg, H., Tran, T.A., Widstrom, C., Hjertman, M., Abrahmsen, L., Berndorff, D., Dinkelborg, L.M., Cyr, J.E., Feldwisch, J., Orlova, A., Tolmachev, V. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine (2009) Journal of Nuclear Medicine, 50 (5), pp. 781-789.
    DOI: 10.2967/jnumed.108.056929
  155. Tolmachev, V., Mume, E., Sjoberg, S., Frejd, F.Y., Orlova, A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules (2009) European Journal of Nuclear Medicine and Molecular Imaging, 36 (4), pp. 692-701.
    DOI: 10.1007/s00259-008-1003-y
  156. Tolmachev, V., Orlova, A. Update on Affibody molecules for in vivo imaging of targets for cancer therapy (2009) Minerva Biotecnologica, 21 (1), pp. 21-30.
  157. Tolmachev, V., Friedman, M., Sandstrom, M., Eriksson, T.L.J., Rosik, D., Hodik, M., Stahl, S., Frejd, F.Y., Orlova, A. Affibody molecules for epidermal growth factor receptor targeting in vivo: Aspects of dimerization and labeling chemistry (2009) Journal of Nuclear Medicine, 50 (2), pp. 274-283.
    DOI: 10.2967/jnumed.108.055525
  158. Tran, T.A., Ekblad, T., Orlova, A., Sandstrom, M., Feldwisch, J., Wennborg, A., Abrahmsen, L., Tolmachev, V., Karlstrom, A.E. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 affibody molecules (2008) Bioconjugate Chemistry, 19 (12), pp. 2568-2576.
    DOI: 10.1021/bc800244b
  159. Tolmachev, V. Choice of radionuclides and radiolabelling techniques (2008) Targeted Radionuclide Tumor Therapy: Biological Aspects, pp. 145-174.
    DOI: 10.1007/978-1-4020-8696-0_8
  160. Ekblad, T., Tran, T., Orlova, A., Widstrom, C., Feldwisch, J., Abrahmsen, L., Wennborg, A., Karlstrom, A.E., Tolmachev, V. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake (2008) European Journal of Nuclear Medicine and Molecular Imaging, 35 (12), pp. 2245-2255.
    DOI: 10.1007/s00259-008-0845-7
  161. Tolmachev, V. Imaging of HER-2 overexpression in tumors for guiding therapy (2008) Current Pharmaceutical Design, 14 (28), pp. 2999-3019.
    DOI: 10.2174/138161208786404290
  162. Tolmachev, V., Xu, H., Wallberg, H., Ahlgren, S., Hjertman, M., Sjoberg, A., Sandstrom, M., Abrahmsen, L., Brechbiel, M.W., Orlova, A. Evaluation of a maleimido derivative of CHX-A? DTPA for site-specific labeling of affibody molecules (2008) Bioconjugate Chemistry, 19 (8), pp. 1579-1587.
    DOI: 10.1021/bc800110y
  163. Steffen, A.-C., Gostring, L., Tolmachev, V., Palm, S., Stenerlow, B., Carlsson, J. Differences in radiosensitivity between three HER2 overexpressing cell lines (2008) European Journal of Nuclear Medicine and Molecular Imaging, 35 (6), pp. 1179-1191.
    DOI: 10.1007/s00259-007-0713-x
  164. Friedman, M., Orlova, A., Johansson, E., Eriksson, T.L.J., Hoiden-Guthenberg, I., Tolmachev, V., Nilsson, F.Y., Stahl, S. Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule (2008) Journal of Molecular Biology, 376 (5), pp. 1388-1402.
    DOI: 10.1016/j.jmb.2007.12.060
  165. Nordberg, E., Orlova, A., Friedman, M., Tolmachev, V., Stahl, S., Nilsson, F.Y., Glimelius, B., Carlsson, J. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells (2008) Oncology Reports, 19 (4), pp. 853-857.
    DOI: 10.3892/or.19.4.853
  1. Ahlgren, S., Orlova, A., Rosik, D., Sandstrom, M., Sjoberg, A., Baastrup, B., Widmark, O., Fant, G., Feldwisch, J., Tolmachev, V. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules (2008) Bioconjugate Chemistry, 19 (1), pp. 235-243.
    DOI: 10.1021/bc700307y
  2. Orlova, A., Rosik, D., Sandstrom, M., Lundqvist, H., Einarsson, L., Tolmachev, V. Evaluation of [111/114mIn]CHX-A"-DTPA-ZHER2:342, an Affibody ligand conjugate for targeting of HER2-expressing malignant tumors (2007) Quarterly Journal of Nuclear Medicine and Molecular Imaging, 51 (4), pp. 314-323.
  3. Nestor, M., Ekberg, T., Dring, J., Van Dongen, G.A.M.S., Wester, K., Tolmachev, V., Anniko, M. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay (2007) Tumor Biology, 28 (5), pp. 253-263.
    DOI: 10.1159/000110898
  4. Tran, T., Engfeldt, T., Orlova, A., Sandstrom, M., Feldwisch, J., Abrahmsen, L., Wennborg, A., Tolmachev, V., Karlstrom, A.E. 99mTc-maEEE-ZHER2:342, an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors (2007) Bioconjugate Chemistry, 18 (6), pp. 1956-1964.
    DOI: 10.1021/bc7002617
  5. Engfeldt, T., Tran, T., Orlova, A., Widstrom, C., Feldwisch, J., Abrahmsen, L., Wennborg, A., Karlstrom, A.E., Tolmachev, V. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34 (11), pp. 1843-1853.
    DOI: 10.1007/s00259-007-0474-6
  6. Orlova, A., Feldwisch, J., Abrahmsen, L., Tolmachev, V. Update: Affibody molecules for molecular imaging and therapy for cancer (2007) Cancer Biotherapy and Radiopharmaceuticals, 22 (5), pp. 573-584.
    DOI: 10.1089/cbr.2006.004-U
  7. Persson, M., Sivaev, I., Winberg, K.J., Gedda, L., Malmstrom, P.-U., Tolmachev, V. In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab (2007) Cancer Biotherapy and Radiopharmaceuticals, 22 (5), pp. 585-596.
    DOI: 10.1089/cbr.2006.338
  8. Cheng, J., Ekberg, T., Engstrom, M., Nestor, M., Jensen, H.J., Tolmachev, V., Anniko, M. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma (2007) Laryngoscope, 117 (6), pp. 1013-1018.
    DOI: 10.1097/MLG.0b013e31804b1a6d
  9. Steffen, A.-C., Almqvist, Y., Chyan, M.-K., Lundqvist, H., Tolmachev, V., Wilbur, D.S., Carlsson, J. Biodistribution of211at labeled HER-2 binding affibody molecules in mice (2007) Oncology Reports, 17 (5), pp. 1141-1147.
  10. Engfeldt, T., Orlova, A., Tran, T., Bruskin, A., Widstrom, C., Karlstrom, A.E., Tolmachev, V. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34 (5), pp. 722-733.
    DOI: 10.1007/s00259-006-0266-4 
  11. Tolmachev, V., Orlova, A., Nilsson, F.Y., Feldwisch, J., Wennborg, A., Abrahmsen, L. Affibody molecules: Potential for in vivo imaging of molecular targets for cancer therapy (2007) Expert Opinion on Biological Therapy, 7 (4), pp. 555-568.
    DOI: 10.1517/14712598.7.4.555
  12. Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandstrom, M., Rosik, D., Carlsson, J., Lundqvist, H., Wennborg, A., Nilsson, F.Y. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule (2007) Cancer Research, 67 (6), pp. 2773-2782.
    DOI: 10.1158/0008-5472.CAN-06-1630
  13. Nilsson, F.Y., Tolmachev, V. Affibody® molecules: New protein domains for molecular imaging and targeted tumor therapy (2007) Current Opinion in Drug Discovery and Development, 10 (2), pp. 167-175.
  14. Tran, T., Engfeldt, T., Orlova, A., Widstrom, C., Bruskin, A., Tolmachev, V., Karlstrom, A.E. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting affibody molecules (2007) Bioconjugate Chemistry, 18 (2), pp. 549-558.
    DOI: 10.1021/bc060291m
  15. Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandstrom, M., Nilsson, F.Y., Wennborg, A., Abrahmsen, L., Feldwisch, J.Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors(2007) Cancer Research, 67 (5), pp. 2178-2186.
    DOI: 10.1158/0008-5472.CAN-06-2887
  16. Fortin, M.-A., Orlova, A., Malmstrom, P.-U., Tolmachev, V. Labelling chemistry and characterization of [90Y/ 177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma (2007) International Journal of Molecular Medicine, 19 (2), pp. 285-291.
    DOI: 10.3892/ijmm.19.2.285
  17. Tran, T., Orlova, A., Sivaev, I., Sandstrom, M., Tolmachev, V. Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand (2007) International Journal of Molecular Medicine, 19 (3), pp. 485-493.
    DOI: 10.3892/ijmm.19.3.485
  18. Almqvist, Y., Steffen, A.-C., Lundqvist, H., Jensen, H., Tolmachev, V., Sundin, A. Biodistribution of 211At-labeled humanized monoclonal antibody A33 (2007) Cancer Biotherapy and Radiopharmaceuticals, 22 (4), pp. 480-487.
    DOI: 10.1089/cbr.2007.349A
  19. Orlova, A., Tran, T., Widstrom, C., Engfeldt, T., Karlstrom, A.E., Tolmachev, V. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z HER2:342, a potential agent for imaging of HER2 expression in malignant tumors (2007) International Journal of Molecular Medicine, 20 (3), pp. 397-404.
    DOI: 10.3892/ijmm.20.3.397
  20. Persson, M., Gedda, L., Lundqvist, H., Tolmachev, V., Nordgren, H., Malmstrom, P.-U., Carlsson, J. [177Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts (2007) Cancer Research, 67 (1), pp. 326-331.
    DOI: 10.1158/0008-5472.CAN-06-2363
  21. Almqvist, Y., Steffen, A.-C., Tolmachev, V., Divgi, C.R., Sundin, A. In vitro and in vivo characterization of 177Lu-huA33. A radioimmunoconjugate against colorectal cancer (2006) Nuclear Medicine and Biology, 33 (8), pp. 991-998.
    DOI: 10.1016/j.nucmedbio.2006.09.003
  22. Steffen, A.-C., Orlova, A., Wikman, M., Nilsson, F.Y., Stahl, S., Adams, G.P., Tolmachev, V., Carlsson, J. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice (2006) European Journal of Nuclear Medicine and Molecular Imaging, 33 (6), pp. 631-638.
    DOI: 10.1007/s00259-005-0012-3
  23. Tolmachev, V., Nilsson, F.Y., Widstrom, C., Andersson, K., Rosik, D., Gedda, L., Wennborg, A., Orlova, A. 111In-Benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors (2006) Journal of Nuclear Medicine, 47 (5), pp. 846-853.
  24. Orlova, A., Magnusson, M., Eriksson, T.L.J., Nilsson, M., Larsson, B., Hoiden-Guthenberg, I., Widstrom, C., Carlsson, J., Tolmachev, V., Stahl, S., Nilsson, F.Y. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule (2006) Cancer Research, 66 (8), pp. 4339-4348.
    DOI: 10.1158/0008-5472.CAN-05-3521
  25. Orlova, A., Bruskin, A., Sivaev, I., Sjoberg, S., Lundqvist, H., Tolmachev, V. Radio-iodination of monoclonal antibody using potassium [ 125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo- dodecaborate (Iodo-DABI) (2006) Anticancer Research, 26 (2 A), pp. 1217-1223.
  26. Orlova, A., Nilsson, F.Y., Wikman, M., Widstrom, C., Stahl, S., Carlsson, J., Tolmachev, V. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors (2006) Journal of Nuclear Medicine, 47 (3), pp. 512-519.
  27. Carlsson, J., Ren, Z.P., Wester, K., Sundberg, A.L., Heldin, N.E., Hesselager, G., Persson, M., Gedda, L., Tolmachev, V., Lundqvist, H., Blomquist, E., Nister, M. Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression (2006) Journal of Neuro-Oncology, 77 (1), pp. 33-45.
    DOI: 10.1007/s11060-005-7410-z
  28. Hoglund, J., Orlova, A., Sundin, A., Lundqvist, H., Tolmachev, V. Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated (2006) Oncology Reports, 16 (1), pp. 159-163.
    DOI: 10.3892/or.16.1.159
  29. Persson, M.I., Gedda, L., Jensen, H.J., Lundqvist, H., Malmstrom, P.-U., Tolmachev, V. Astatinated trastuzumab, aputative agent for radionuclide immunotherapy of ErbB2-expressing tumours (2006) Oncology Reports, 15 (3), pp. 673-680.
    DOI: 10.3892/or.15.3.673
  30. Persson, M., Tolmachev, V., Andersson, K., Gedda, L., Sandstrom, M., Carlsson, J. [177Lu]pertuzumab: Experimental studies on targeting of HER-2 positive tumour cells (2005) European Journal of Nuclear Medicine and Molecular Imaging, 32 (12), pp. 1457-1462.
    DOI: 10.1007/s00259-005-1902-0
  31. Almqvist, Y., Orlova, A., Sjostrom, A., Jensen, H.J., Lundqvist, H., Sundin, A., Tolmachev, V. In vitro characterization of 211At-labeled antibody A33 - A potential therapeutic agent against metastatic colorectal carcinoma (2005) Cancer Biotherapy and Radiopharmaceuticals, 20 (5), pp. 514-523.
    DOI: 10.1089/cbr.2005.20.514
  32. Mume, E., Orlova, A., Larsson, B., Nilsson, A.-S., Nilsson, F.Y., Sjoberg, S., Tolmachev, V. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody (2005) Bioconjugate Chemistry, 16 (6), pp. 1547-1555.
    DOI: 10.1021/bc050056o
  33. Nestor, M., Persson, M., Van Dongen, G.A.M.S., Jensen, H.J., Lundqvist, H., Anniko, M., Tolmachev, V. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma (2005) European Journal of Nuclear Medicine and Molecular Imaging, 32 (11), pp. 1296-1304.
    DOI: 10.1007/s00259-005-1848-2
  34. Velikyan, I., Sundberg, A.L., Lindhe, O., Hoglund, A.U., Eriksson, O., Werner, E., Carlsson, J., Bergstrom, M., Langstrom, B., Tolmachev, V. Preparation and evaluation of 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors (2005) Journal of Nuclear Medicine, 46 (11), pp. 1881-1888.
  35. Ghirmai, S., Mume, E., Lundqvist, H., Tolmachev, V., Sjoberg, S. Synthesis and radioiodination of some 9-aminoacridine derivatives for potential use in radionuclide therapy (2005) Journal of Labelled Compounds and Radiopharmaceuticals, 48 (12), pp. 855-871.
    DOI: 10.1002/jlcr.960
  36. Mume, E., Orlova, A., Malmstrom, P.-U., Lundqvist, H., Sjoberg, S., Tolmachev, V. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET (2005) Nuclear Medicine and Biology, 32 (6), pp. 613-622.
    DOI: 10.1016/j.nucmedbio.2005.04.010
  37. Steffen, A.-C., Wikman, M., Tolmachev, V., Adams, G.P., Nilsson, F.Y., Stahl, S., Carlsson, J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics (2005) Cancer Biotherapy and Radiopharmaceuticals, 20 (3), pp. 239-248.
    DOI: 10.1089/cbr.2005.20.239
  38. Winberg, K.J., Mume, E., Tolmachev, V., Sjoberg, S. Radiobromination of closo-carboranes using palladium-catalyzed halogen exchange (2005) Journal of Labelled Compounds and Radiopharmaceuticals, 48 (3), pp. 195-202.
    DOI: 10.1002/jlcr.914
  39. Ghirmai, S., Mume, E., Tolmachev, V., Sjoberg, S. Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives (2005) Carbohydrate Research, 340 (1), pp. 15-24.
    DOI: 10.1016/j.carres.2004.10.014
  40. Babaei, M.H., Almqvist, Y., Orlova, A., Shafii, M., Kairemo, K., Tolmachev, V. [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: Preparation and pre-clinical evaluation (2005) Oncology Reports, 13 (6), pp. 1169-1175.
    DOI: 10.3892/or.13.6.1169
  41. Kullberg, E.B., Stenerlow, B., Ghirmai, S., Lundqvist, H., Malmstrom, P.-U., Orlova, A., Tolmachev, V., Gedda, L. An aminoacridine derivative for radionuclide therapy: DNA-binding properties studied in a novel cell-free in vitro assay (2005) International Journal of Oncology, 27 (5), pp. 1355-1360.
    DOI: 10.3892/ijo.27.5.1355
  42. Sandstrom, M., Tolmachev, V., Kairemo, K., Lundqvist, H., Lubberink, M. Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT (2004) Physics in Medicine and Biology, 49 (24), pp. 5419-5432.
    DOI: 10.1088/0031-9155/49/24/002
  43. Cheng, J., Persson, M., Tolmachev, V., Siavaev, I., Orlova, A., Kairemo, K., Anniko, M. Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate- containing linker (2004) Acta Oto-Laryngologica, 124 (9), pp. 1078-1085.
    DOI: 10.1080/00016480410017891
  44. Orlova, A., Sjostrom, A., Lebeda, O., Lundqvist, H., Carlsson, J., Tolmachev, V. Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells (2004) Anticancer Research, 24 (6), pp. 4035-4041.
  45. Tolmachev, V., Orlova, A., Wei, Q., Bruskin, A., Carlsson, J., Gedda, L. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-HEGF and [111In]Bz-DTPA-hEGF in normal mice (2004) Cancer Biotherapy and Radiopharmaceuticals, 19 (4), pp. 491-501.
    DOI: 10.1089/cbr.2004.19.491
  46. Ghirmai, S., Mume, E., Henssen, C., Ghaneolhusseini, H., Lundqvist, H., Tolmachev, V., Sjoberg, S., Orlova, A. Synthesis and radioiodination of some 9-aminoacridine derivatives(2004) European Journal of Organic Chemistry, (17), pp. 3719-3725.
    DOI: 10.1002/ejoc.200400296
  47. Shchukin, E., Orlova, A., Korsakov, M., Sjoberg, S., Tolmachev, V. Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media (2004) Journal of Radioanalytical and Nuclear Chemistry, 260 (2), pp. 295-299.
    DOI: 10.1023/B:JRNC.0000027099.63853.cc
  48. Orlova, A., Sivaev, I., Sjoberg, S., Lundqvist, H., Tolmachev, V. Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB 11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T (2004) Radiochimica Acta, 92 (4-6), pp. 311-315.
    DOI: 10.1524/ract.92.4.311.35595
  49. Ghirmai, S., Malmquist, J., Lundquist, H., Tolmachev, V., Sjoberg, S. Synthesis and radioiodination of 7-(3?-ammoniopropyl)-7, 8-dicarba-nido-undecaborate (-1),(ANC) //Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal of the International Isotope Society. – 2004. – Т. 47. – №. 9. – С. 557-569.
    DOI: 10.1002/jlcr.840
  50. Tolmachev, V., Bruskin, A., Sjoberg, S., Carlsson, J., Lundqvist, H. Preparation, radioiodination and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides //Journal of radioanalytical and nuclear chemistry. – 2004. – Т. 261. – №. 1. – С. 107-112.
    DOI: 10.1023/B:JRNC.0000030942.76919.6b
  51. Tolmachev, V., Carlsson, J., Lundqvist, H. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy Availability of suitable radionuclides //Acta Oncologica. – 2004. – Т. 43. – №. 3. – С. 264-275.
    DOI: 10.1080/02841860410028943
  52. Sundberg, A.L., Gedda, L., Orlova, A., Bruskin, A., Blomquist, E., Carlsson, J., Tolmachev, V. [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma//Cancer biotherapy & radiopharmaceuticals. – 2004. – Т. 19. – №. 2. – С. 195.
    DOI: 10.1089/108497804323071977
  53. Winberg, K.J., Persson, M., Malmstrom, P.-U., Sjoberg, S., Tolmachev, V. Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br] undecahydro-bromo-7, 8-dicarba-nido-undecaborate (1-) ion //Nucl Med Biol. – 2004. – Т. 31. – №. 4. – С. 425-33.
    DOI: 10.1016/j.nucmedbio.2003.11.007
  54. Wikman, M., Steffen, A.-C., Gunneriusson, E., Tolmachev, V., Adams, G.P., Carlsson, J., Stahl, S. Selection and characterization of HER2/neu-binding affibody ligand //Protein Engineering, Design & Selection. – 2004. – Т. 17. – С. 455-62.
    DOI: 10.1093/protein/gzh053
  55. Lundqvist, H., Carlsson, J., Gedda, L., Tolmachev, V., Garske, U., Kairemo, K. Radionuclide therapy - A possible way to improve treatment of cancer [Radionuklidterapi - Mojlig vag mot battre behandling av cancer: Hindret ar bristen pa kommersiellt tillgangliga nuklider i kliniken] (2004) Lakartidningen, 101 (11), pp. 1000-1006.
  56. Bruskin, A., Sivaev, I., Persson, M., Lundqvist, H., Carlsson, J., Sjoberg, S., Tolmachev, V. Radiobromination of monoclonal antibody using isothiocyanato derivative of closo-dodecaborate ([76Br] Bromo-DABI) //Nucl Med Biol. – 2004. – Т. 31. – С. 205-211.
    DOI: 10.1016/j.nucmedbio.2003.08.005
  57. Tolmachev, V., Orlova, A., Lundqvist, H. Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides //Current medicinal chemistry. – 2003. – Т. 10. – №. 22. – С. 2447-2460.
    DOI: 10.2174/0929867033456666
  58. Sundberg, A.L., Almqvist, Y., Orlova, A., Blomquist, E., Jensen, H.J., Gedda, L., Tolmachev, V., Carlsson, J. Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211 At-EGF //European journal of nuclear medicine and molecular imaging. – 2003. – Т. 30. – №. 10. – С. 1348-1356.
    DOI: 10.1007/s00259-003-1308-9
  59. Winberg, K.J., Barbera, G., Eriksson, L., Teixidor, F., Tolmachev, V., Vinas, C., Sjoberg, S. High yield [125I] iodide-labeling of iodinated carboranes by palladium-catalyzed isotopic exchange //Journal of organometallic chemistry. – 2003. – Т. 680. – №. 1-2. – С. 188-192.
    DOI: 10.1016/S0022-328X(03)00344-9
  60. Nestor, M., Persson, M., Cheng, J., Tolmachev, V., Van Dongen, G., Anniko, M., Kairemo, K. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods //Bioconjugate chemistry. – 2003. – Т. 14. – №. 4. – С. 805-810.
    DOI: 10.1021/bc034003n
  61. Sundberg, A.L., Almqvist, Y., Tolmachev, V., Carlsson, J. Treatment of cultured glioma cells with the EGFR-TKI gefitinib (" Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition //European Journal of Nuclear Medicine and Molecular Imaging. – 2003. – Т. 30. – №. 5. – С. 727-729.
    DOI: 10.1007/s00259-003-1129-x
  62. Sjostrom, A., Tolmachev, V., Lebeda, O., Koziorowski, J., Carlsson, J., Lundqvist, H. Direct astatination of a tumour-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group //Journal of radioanalytical and nuclear chemistry. – 2003. – Т. 256. – №. 2. – С. 191-197.
    DOI: 10.1023/A:1023912728929
  63. Korsakov, M.V., Shchukin, E.V., Korsakova, L.N., Orlova, A.M., Sjoberg, S., Tolmachev, V. Feasibility of isotopic exchange in the system [125I] iodide-undecahydro-iodo-closo-dodecaborate (2-) anion //Journal of radioanalytical and nuclear chemistry. – 2003. – Т. 256. – №. 1. – С. 67-71.
    DOI: 10.1023/A:1023348025353
  64. Beshara, S., Sorensen, J., Lubberink, M., Tolmachev, V., Langstrom, B., Antoni, G., Danielson, B.G., Lundqvist, H. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography //British journal of haematology. – 2003. – Т. 120. – №. 5. – С. 853-859.
    DOI: 10.1046/j.1365-2141.2003.03590.x
  65. Eriksson, L., Tolmachev, V., Sjoberg, S. Feasibility of palladium-catalyzed isotopic exchange between sodium [125I] I and 2-iodo-para-carborane //Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal of the International Isotope Society. – 2003. – Т. 46. – №. 7. – С. 623-631.
    DOI: 10.1002/jlcr.702
  66. Sundberg, A., Orlova, A., Bruskin, A., Gedda, L., Carlsson, J., Blomquist, E., Lundqvist, H., Tolmachev, V. [111In] Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent //Cancer Biotherapy and Radiopharmaceuticals. – 2003. – Т. 18. – №. 4. – С. 643-654.
    DOI: 10.1089/108497803322287736
  67. Lundqvist, H., Tolmachev, V. Targeting peptides and positron emission tomography //Peptide Science: Original Research on Biomolecules. – 2002. – Т. 66. – №. 6. – С. 381-392.
    DOI: 10.1002/bip.10348
  68. Lubberink, M., Tolmachev, V., Widstrom, C., Bruskin, A., Lundqvist, H., Westlin, J.-E. 10mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET (2002) Journal of Nuclear Medicine, 43 (10), pp. 1391-1397.
  69. Tolmachev, V., Sjoberg, S. Polyhedral boron compounds as potential linkers for attachment of radiohalogens to targeting proteins and peptides. A review //Collection of Czechoslovak chemical communications. – 2002. – Т. 67. – №. 7. – С. 913-935.
    DOI: 10.1135/cccc20020913
  70. Tolmachev, V., Orlova, A., Sundin, A. Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent //Journal of radioanalytical and nuclear chemistry. – 2002. – Т. 251. – №. 3. – С. 409-412.
    DOI: 10.1023/A:1014873923439
  71. Lubberink, M., Lundqvist, H., Tolmachev, V. Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy //Physics in Medicine & Biology. – 2002. – Т. 47. – №. 4. – С. 615.
    DOI: 10.1088/0031-9155/47/4/305
  72. Lindqvist, U., Tolmachev, V., Kairemo, K., Astrom, G., Jonsson, E., Lundqvist, H. Elimination of stabilised hyaluronan from the knee joint in healthy men //Clinical pharmacokinetics. – 2002. – Т. 41. – №. 8. – С. 603-613.
    DOI: 10.2165/00003088-200241080-00004
  73. Tolmachev, V., Bruskin, A., Lundqvist, H., Sivaev, I., Sjoberg, S., Bruskin, A., Sivaev, I. Radiobromination of closo-dodecaborate anion. Aspects of labelling chemistry in aqueous solution using Chloramine-T //Radiochimica Acta. – 2002. – Т. 90. – №. 4. – С. 229-235.
    DOI: 10.1524/ract.2002.90.4_2002.229
  74. Orlova, A., Hooglund, J., Lubberink, M., Lebeda, O., Gedda, L., Lundqvist, H., Tolmachev, V., Sundin, A. Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry //Cancer Biotherapy and Radiopharmaceuticals. – 2002. – Т. 17. – №. 4. – С. 385-396.
    DOI: 10.1089/108497802760363187
  75. Tolmachev, V., Lundqvist, H. Separation of arsenic from germanium oxide targets by dry distillation //Journal of Radioanalytical and Nuclear Chemistry. – 2001. – Т. 247. – №. 1. – С. 61-66.
    DOI: 10.1023/A:1006706913108
  76. Bruskin, A., Tolmachev, V., Westlin, J.-E., Lundqvist, H. Separation of two labeled components of [111In]-OctreoScan by HPLC (2001) Journal of Radioanalytical and Nuclear Chemistry, 247 (1), pp. 95-99.
    DOI: 10.1023/A:1006715114925
  77. Mars, U., Tolmachev, V., Sundin, A. Positron emission tomography of experimental melanoma with [76Br] 5-bromo-2-thiouracil //Nuclear Medicine and Biology. – 2000. – Т. 27. – №. 8. – С. 845-849.
    DOI: 10.1016/S0969-8051(00)00147-5
  78. Hoglund, J., Tolmachev, V., Orlova, A., Lundqvist, H., Sundin, A. Optimized indirect 76Br-bromination of antibodies using N-succinimidyl para-[76Br] bromobenzoate for radioimmuno PET //Nuclear medicine and biology. – 2000. – Т. 27. – №. 8. – С. 837-843.
    DOI: 10.1016/S0969-8051(00)00153-0
  79. Orlova, A., Bruskin, A., Sjostrom, A., Lundqvist, H., Gedda, L., Tolmachev, V. Cellular processing of 125I-and 111In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells //Nuclear medicine and biology. – 2000. – Т. 27. – №. 8. – С. 827-835.
    DOI: 10.1016/S0969-8051(00)00148-7
  80. Orlova, A., Lebeda, O., Tolmachev, V., Sjoberg, S., Carlsson, J., Lundqvist, H. Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T //Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal of the International Isotope Society. – 2000. – Т. 43. – №. 3. – С. 251-260.
    DOI: 10.1002/(SICI)1099-1344(20000315)43:3<251::AID-JLCR311>3.0.CO;2-Z
  81. Tolmachev, V., Bernhardt, P., Forssell-Aronsson, E., Lundqvist, H. 114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide //Nuclear medicine and biology. – 2000. – Т. 27. – №. 2. – С. 183-188.
    DOI: 10.1016/S0969-8051(99)00096-7
  82. Tolmachev, V., Orlova, A., Lundqvist, H. Optimization of iodination of [125I]-N-succinimidyl-para-iodobenzoate using Chloramine-T for labeling of proteins //Journal of Radioanalytical and Nuclear Chemistry. – 2000. – Т. 246. – №. 1. – С. 207-213.
    DOI: 10.1023/A:1006755103374
  83. Lubberink, M., Tolmachev, V., Beshara, S., Lundqvist, H. Quantification aspects of patient studies with 52Fe in positron emission tomography //Applied radiation and isotopes. – 1999. – Т. 51. – №. 6. – С. 707-715.
    DOI: 10.1016/S0969-8043(99)00105-0
  84. Zhao, Q., Tolmachev, V., Carlsson, J., Lundqvist, H., Sundin, J., Janson, J.-C., Sundin, A. Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF //Bioconjugate chemistry. – 1999. – Т. 10. – №. 6. – С. 938-946.
    DOI: 10.1021/bc990011l
  85. Sundin, J., Tolmachev, V., Koziorowski, J., Carlsson, J., Lundqvist, H., Welt, S., Larson, S., Sundin, A. High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T //Nuclear medicine and biology. – 1999. – Т. 26. – №. 8. – С. 923-929.
    DOI: 10.1016/S0969-8051(99)00076-1
  86. Lubberink, M., Lundqvist, H., Westlin, J.-E., Tolmachev, V., Schneider, H., Lovqvist, A., Sundin, A., Carlsson, J. Positron emission tomography and radioimmunotargeting: Aspects of quantification and dosimetry //Acta Oncologica. – 1999. – Т. 38. – №. 3. – С. 343-349.
    DOI: 10.1080/028418699431429
  87. Lundqvist, H., Lubberink, M., Tolmachev, V., Lovqvist, A., Sundin, A., Beshara, S., Bruskin, A., Carlsson, J., Westlin, J.-E. Positron emission tomography and radioimmunotargeting: general aspects //Acta Oncologica. – 1999. – Т. 38. – №. 3. – С. 335-341.
    DOI: 10.1080/028418699431410
  88. Carlsson, J., Blomquist, E., Gedda, L., Liljegren, A., Malmstrom, P.-U., Sjostrom, A., Sundin, A., Westlin, J.-E., Zhao, Q., Tolmachev, V., Lundqvist, H. Conjugate chemistry and cellular processing of EGF-dextran //Acta Oncologica. – 1999. – Т. 38. – №. 3. – С. 313-321.
    DOI: 10.1080/028418699431384
  89. Tolmachev, V., Koziorowski, J., Sivaev, I., Lundqvist, H., Carlsson, J., Orlova, A., Gedda, L., Olsson, P., Sjoberg, S., Sundin, A. Closo-dodecaborate (2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution //Bioconjugate chemistry. – 1999. – Т. 10. – №. 3. – С. 338-345.
    DOI: 10.1021/bc980033s
  90. Beshara, S., Lundqvist, H., Sundin, J., Lubberink, M., Tolmachev, V., Valind, S., Antoni, G., Langstrom, B., Danielson, B.G. Pharmacokinetics and red cell utilization of iron (III) hydroxide–sucrose complex in anaemic patients: a study using positron emission tomography //British journal of haematology. – 1999. – Т. 104. – №. 2. – С. 296-302.
    DOI: 10.1046/j.1365-2141.1999.01179.x
  91. Beshara, S., Lundqvtst, H., Sundin, J., Lubberink, M., Tolmachev, V., Valind, S., Antoni, G., Langstrom, B., Danielson, B.G. Kinetic analysis of 52Fe-labelled iron (III) hydroxide–sucrose complex following bolus administration using positron emission tomography //British journal of haematology. – 1999. – Т. 104. – №. 2. – С. 288-295.
    DOI: 10.1046/j.1365-2141.1999.01170.x
  92. Garberg, P., Engman, L., Tolmachev, V., Lundqvist, H., Gerdes, R.G., Cotgreave, I.A. Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase //The international journal of biochemistry & cell biology. – 1999. – Т. 31. – №. 2. – С. 291-301.
    DOI: 10.1016/S1357-2725(98)00113-7
  93. Tolmachev, V., Bernhardt, P., Forssell-Aronsson, E., Lundqvist, H. [114mIn]-DTPA-D-Phe1-octreotide - A candidate for radionuclide therapy (1999) Journal of Labelled Compounds and Radiopharmaceuticals, 42 (SUPPL. 1), pp. S726-S728.
  94. Tolmachev, V., Bennarsten, J., Bruskin, A., Carlsson, J., Lundqvist, H. Radioiodinated nido-carborane-dextran conjugate, a potential residulizing labels. Preparation and comparative in vitro stability study (1999) Journal of Labelled Compounds and Radiopharmaceuticals, 42 (SUPPL. 1), pp. S765-S767.
  95. Sundin, J., Tolmachev, V., Orlova, A., Lundqvist, H., Sundin, A. High yield 76Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate (1999) Journal of Labelled Compounds and Radiopharmaceuticals, 42 (SUPPL. 1), pp. S768-S770.
  96. Yngve, U., Hedberg, E., Lovqvist, A., Tolmachev, V., Langstrom, B. Synthesis of N-succinimidyl 4-[76 Br] bromobenzoate and its use in conjugation labelling of macromolecules //Acta Chemica Scandinavica (1989). – 1999. – Vol. 53. – P. 508-512.
    DOI: 10.3891/acta.chem.scand.53-0508
    https://inis.iaea.org/search/search.aspx?orig_q=RN:30043870
  97. Orlova, A., Lebeda, O., Tolmachev, V., Sjoberg, S., Carlsson, J., Lundqvist, H. Astatination of closo-dodecaborate (2-) anion (1999) Journal of Labelled Compounds and Radiopharmaceuticals, 42 (SUPPL. 1), pp. S735-S737.
  98. Lovqvist, A., Lundqvist, H., Lubberink, M., Tolmachev, V., Carlsson, J., Sundin, A. Kinetics of-labeled anti-CEA antibodies in pigs; Aspects of dosimetry and PET imaging properties //Medical Physics. – 1999. – Vol. 26. – No. 2. – P. 249-258.
    DOI: 10.1118/1.598512
  99. Orlova, A., Koziorowski, J., Henssen, C., Ghaneolhosseini, H., Lundqvist, H., Tolmachev, V., Sjoberg, S. Radiolabelling of acridines with potential use in cancer therapy (1999) Journal of Labelled Compounds and Radiopharmaceuticals, 42 (SUPPL. 1), pp. S738-S740.
  100. Tolmachev, V., Lovqvist, A., Einarsson, L., Schultz, J., Lundqvist, H. Production of 76Br by a low-energy cyclotron //Applied radiation and isotopes. – 1998. – Vol. 49. – No. 12. – P. 1537-1540.
    DOI: 10.1016/S0969-8043(97)10129-4
    https://www.sciencedirect.com/science/article/pii/S0969804397101294?casa_token=wpR6RR0qmnYAAAAA:00wrijCJVQKTUN7iB5IVyhXe68OsTUU2PkECvfy1Lm8ESjzeI8yshPwzCZ8iJQqhBWX-kg1lNLg
  101. Lundqvist, H., Lubberink, M., Tolmachev, V. Positron emission tomography // European Journal of Physics. – 1998. – Vol. 19. – No. 6. – P. 537-552.
    DOI: 10.1088/0143-0807/19/6/007
  102. Bergstrom, M., Lu, L., Fasth, K.-J., Wu, F., Bergstrom-Pettermann, E., Tolmachev, V., Hedberg, E., Cheng, A., Langstrom, B In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker //The Journal of Nuclear Medicine. – 1998. – Vol. 39. – No. 7. – P. 1273.
    https://search.proquest.com/openview/148ba01e52f9ed26270c571ac17047bc/1?pq-origsite=gscholar&cbl=40808
  103. Tolmachev, V., Lundqvist, H., Einarsson, L. Production of 61Cu from a natural nickel target //Applied radiation and isotopes. – 1998. – Vol. 49. – No. 1-2. – P. 79-81.
    DOI: 10.1016/S0969-8043(97)00235-2
    https://www.sciencedirect.com/science/article/abs/pii/S0969804397002352
  104. Zhao, Q., Blomquist, E., Bolander, H., Gedda, L., Hartvig, P., Janson, J., Lundqvist, H., Mellstedt, H., Nilsson, S., Nister, M., Sundin, A., Tolmachev, V., Westlin, J., Carlsson, J. Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials //International journal of molecular medicine. – 1998. – Vol. 1. – No. 4. – P. 693-1395.
    DOI: 10.3892/ijmm.1.4.693
    https://www.spandidos-publications.com/ijmm/1/4/693
  105. Tolmachev, V., Lundqvist, H., Einarsson, L. Diffusion-based separation methods: dry distillation of zinc, cadmium and mercury isotopes from irradiated targets //Applied radiation and isotopes. – 1997. – Vol. 48. – No. 5. – P. 565-569.
    DOI: 10.1016/S0969-8043(96)00339-9
    https://www.sciencedirect.com/science/article/abs/pii/S0969804396003399
  106. Tolmachev, V., Lundqvist, H. Rapid separation of gallium from zinc targets by thermal diffusion //Applied radiation and isotopes. – 1996. – Vol. 47. – No. 3. – P. 297-299.
    DOI: 10.1016/0969-8043(95)00290-1
    https://www.sciencedirect.com/science/article/abs/pii/0969804395002901
  107. Lundqvist, H., Tolmachev, V., Bruskin, A., Einarsson, L., Malmborg, P. Rapid separation of 110In from enriched Cd targets by thermal diffusion //Applied radiation and isotopes. – 1995. – Vol. 46. – No. 9. – P. 859-863.
    DOI: 10.1016/0969-8043(95)00183-E
    https://www.sciencedirect.com/science/article/abs/pii/096980439500183E